Skip to main content

Featured Studies

This web page makes it easy to search for featured research studies at the NIH Clinical Center. You can search for specific studies by entering keywords related to your symptoms in the search box or by using the sort and filter options.


To view a full list of all studies conducted at the NIH Clinical Center, visit Search the Studies.

Filter By

Visit Type

Patient or Healthy Volunteer

Age Group

Web Page Language

136 results
An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children with Growth Hormone Excess

An Open-Label Phase 3 Study of the Safety and Efficacy of Pegvisomant in Children with Growth Hormone Excess

Gigantism is a condition characterized by excessive growth and height significantly above average, caused by over-production of growth hormone (GH) during childhood. Investigators at the National Institutes of Health (NIH) want to see if a drug that antagonizes growth hormone action, called pegvisomant, can help children and adolescents with gigantism.
Learn More
A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)

A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects with Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)

Hepatocellular Carcinoma (HCC) is the fifth most common cancer in the world. Patients with advanced HCC survive an average of 6 to 9 months. Researchers at the National Institutes of Health are testing the use of an immunotherapy medication called durvalumab, with two other chemotherapy medications, doxorubicin-eluting beads and bevacizumab. This clinical research study will investigate if this combination of medications can stop the progression of HCC.
Learn More
Men at High Genetic Risk for Prostate Cancer

Men at High Genetic Risk for Prostate Cancer

Join a National Institutes of Health (NIH) research study seeking mean men who have a genetic risk factor for developing prostate cancer. Researchers want to follow the prostate health of men who have specific genetic changes associated with prostate cancer to help them learn more about which men are at higher risk for prostate cancer.
Learn More
Phase II Trial Evaluating Nivolumab in Patients with IDH-Mutant Gliomas with and without Hypermutator Phenotype

Phase II Trial Evaluating Nivolumab in Patients with IDH-Mutant Gliomas with and without Hypermutator Phenotype

National Cancer Institute (NCI) researchers are conducting a study of patients with IDH-mutated gliomas. This study will test whether stimulating the immune system using the drug nivolumab can shrink recurrent IDH-mutant gliomas with and without hypermutator phenotype or increase the time it takes for them to grow or spread.

Learn More
Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease

Genotype -Phenotype Correlation of PKLR Variants with Pyruvate Kinase, 2,3-Diphosphglycerate and ATP Activities in Red Blood Cells of Patients with Sickle Cell Disease

Doctors at the National Institutes of Health (NIH) seek healthy volunteers (with or without a sickle cell trait) and patients with sickle cell for a research study. Sickle cell disease is a genetic blood disorder that occurs mainly in people of African descent. Study participants will have a one-time visit to the NIH to provide blood samples. Researchers hope this study will help us better understand sickle cell disease.
Learn More
Low-Dose Danazol for the Treatment of Telomere Related Diseases

Low-Dose Danazol for the Treatment of Telomere Related Diseases

Researchers at the National Institutes of Health (NIH) are studying if the medication danazol can be used to treat people with short telomere disease who also have bone marrow failure, liver, or lung disease. In recent studies, danazol, at high doses, showed a positive influence on telomere length. Additional research is needed to learn more about the role of different doses of danazol on telomere disease as well as its effects on secondary diseases.

Learn More
Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers with or at high-risk for Cerebral Palsy and Autism Spectrum Disorder Compared to Infants and Toddlers with Typical Development

Near-infrared Spectroscopy and Electroencephalography to Assess Cortical Activation During Motor Tasks in Infants and Toddlers with or at high-risk for Cerebral Palsy and Autism Spectrum Disorder Compared to Infants and Toddlers with Typical Development

Researchers at the National Institutes of Health are conducting a research study to learn more about the motor skill and brain development of infants who are at high-risk for or diagnosed with Cerebral Palsy (CP) and Autism Spectrum Disorder (ASD) compared to infants with typical development. The results of this study may assist with better methods for early diagnosis as well as improved treatment for children with CP and ASD. The results of this study may eventually assist with better methods for early diagnosis as well as improved treatment for children with autism.
Learn More
An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease and Maintenance Therapy with Ustekinumab

An Open-Label, Proof of Concept Study of Vorinostat for the Treatment of Moderate-to-Severe Crohn s Disease and Maintenance Therapy with Ustekinumab

Crohn's disease is a chronic bowel illness that is a lifelong condition characterized by relapsing inflammation. Although there is no cure for Crohn's disease, researchers at the National Institutes of Health (NIH) are investigating if Vorinostat is safe for people with Crohn's Disease. Participants will receive maintenance therapy with Stelara® after successful treatment with Vorinostat.
Learn More
Was this page helpful?